Redx Pharma sees potential for RXC004 as a combination therapy
News release
by
Redx Pharma PLC
London, UK
|
March 13, 2023 08:32 AM Eastern Daylight Time
Redx Pharma PLC (AIM:REDX) chief medical officer Dr Jane Robertson speaks to Proactive's Thomas Warner after announcing that phase II data from the first group of patients being administered RXC004 for biliary tract cancer was not enough to support further development.
Robertson highlights RXC004's potential for use as a combination therapy.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
